Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events-Reference-Cited by-同舟云学术

Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events

Published:2017-05-18 Issue:9 Volume:40 Page:732-739
ISSN:0160-9289
Container-title:Clinical Cardiology
language:en
Short-container-title:Clin Cardiol

Author:

Bavry Anthony A.¹²^ORCID,Elgendy Islam Y.¹^ORCID,Elbez Yedid³⁴,Mahmoud Ahmed N.¹,Sorbets Emmanuel³⁴⁵^ORCID,Steg Philippe Gabriel³⁴⁶,Bhatt Deepak L.⁷^ORCID,

Affiliation:

1. Department of MedicineUniversity of Florida Gainesville Florida

2. North Florida/South Georgia Veterans Health System Gainesville Florida

3. Département Hospitalo‐Universitaire FIREUniversité Paris Diderot, AP‐HP, Hôpital Bichat, and INSERM U‐1148 Paris France

4. FACT (French Alliance for Cardiovascular Clinical Trials)Hôpital Bichat, Assistance Publique‐Hôpitaux de Paris Paris France

5. Service de cardiologieHôpital Avicenne, AP‐HP, and Université Paris 13 Bobigny France

6. National Heart and Lung InstituteRoyal Brompton Hospital Imperial College London United Kingdom

7. Brigham and Women's Hospital Heart and Vascular CenterHarvard Medical School Boston Massachusetts

Funder

sanofiaventis

Bristol-Myers Squibb

Waksman Foundation

World Heart Federation

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clc.22724

Reference29 articles.

1. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group;Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2;Lancet,1988

2. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke

3. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

4. 2013 ESC guidelines on the management of stable coronary artery disease

5. Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanogels with covalently bound and releasable trehalose for autophagy stimulation in atherosclerosis;Journal of Nanobiotechnology;2023-12-08

2. Self-eating in the plaque: nanogels with covalently bound and releasable trehalose for autophagy stimulation in atherosclerosis;2023-09-01

3. Effect of aspirin in patients with established asymptomatic carotid atherosclerosis: A systematic review and meta-analysis;Frontiers in Pharmacology;2022-12-07

4. The Future of Aspirin Therapy in Cardiovascular Disease;The American Journal of Cardiology;2021-04

5. Antiplatelet therapy for the prevention of atherosclerosis in chronic kidney disease (ALTAS-CKD) patients: study protocol for a randomized clinical trial;Trials;2021-01-07